nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—melanoma—germ cell cancer	0.327	0.518	CtDrD
Vemurafenib—skin cancer—germ cell cancer	0.304	0.482	CtDrD
Vemurafenib—ABCC1—Dactinomycin—germ cell cancer	0.0541	0.198	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—germ cell cancer	0.0362	0.132	CbGbCtD
Vemurafenib—ABCC1—Vinblastine—germ cell cancer	0.0339	0.124	CbGbCtD
Vemurafenib—ABCC1—Etoposide—germ cell cancer	0.0306	0.112	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—germ cell cancer	0.0208	0.076	CbGbCtD
Vemurafenib—ABCG2—Etoposide—germ cell cancer	0.0204	0.0747	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—germ cell cancer	0.0202	0.0737	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—germ cell cancer	0.0135	0.0493	CbGbCtD
Vemurafenib—ALB—Methotrexate—germ cell cancer	0.00931	0.034	CbGbCtD
Vemurafenib—CYP3A4—Ifosfamide—germ cell cancer	0.00924	0.0338	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—germ cell cancer	0.00843	0.0308	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—germ cell cancer	0.00771	0.0282	CbGbCtD
Vemurafenib—CYP3A4—Vinblastine—germ cell cancer	0.0049	0.0179	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—germ cell cancer	0.00442	0.0161	CbGbCtD
Vemurafenib—Hyperkeratosis—Bleomycin—germ cell cancer	0.00177	0.0454	CcSEcCtD
Vemurafenib—Rash papular—Ifosfamide—germ cell cancer	0.00116	0.0297	CcSEcCtD
Vemurafenib—CYP1A2—urine—germ cell cancer	0.000774	0.033	CbGeAlD
Vemurafenib—RAF1—neck—germ cell cancer	0.000754	0.0321	CbGeAlD
Vemurafenib—Folliculitis—Dactinomycin—germ cell cancer	0.000751	0.0192	CcSEcCtD
Vemurafenib—Polyp—Ifosfamide—germ cell cancer	0.000711	0.0182	CcSEcCtD
Vemurafenib—Sunburn—Methotrexate—germ cell cancer	0.000677	0.0174	CcSEcCtD
Vemurafenib—RAF1—trigeminal ganglion—germ cell cancer	0.000651	0.0277	CbGeAlD
Vemurafenib—Cyst—Ifosfamide—germ cell cancer	0.000647	0.0166	CcSEcCtD
Vemurafenib—BRAF—uterus—germ cell cancer	0.000636	0.0271	CbGeAlD
Vemurafenib—RAF1—embryo—germ cell cancer	0.000629	0.0268	CbGeAlD
Vemurafenib—BRAF—pituitary gland—germ cell cancer	0.000625	0.0266	CbGeAlD
Vemurafenib—Hepatotoxicity—Dactinomycin—germ cell cancer	0.000611	0.0157	CcSEcCtD
Vemurafenib—RAF1—brainstem—germ cell cancer	0.000576	0.0245	CbGeAlD
Vemurafenib—RAF1—eye—germ cell cancer	0.000561	0.0239	CbGeAlD
Vemurafenib—CYP3A4—urine—germ cell cancer	0.00056	0.0239	CbGeAlD
Vemurafenib—Hepatotoxicity—Ifosfamide—germ cell cancer	0.00056	0.0143	CcSEcCtD
Vemurafenib—BRAF—adrenal gland—germ cell cancer	0.000558	0.0238	CbGeAlD
Vemurafenib—CYP2D6—urine—germ cell cancer	0.000551	0.0235	CbGeAlD
Vemurafenib—BRAF—midbrain—germ cell cancer	0.000551	0.0235	CbGeAlD
Vemurafenib—Neoplasm—Vinblastine—germ cell cancer	0.000542	0.0139	CcSEcCtD
Vemurafenib—BRAF—bone marrow—germ cell cancer	0.00054	0.023	CbGeAlD
Vemurafenib—BRAF—female gonad—germ cell cancer	0.00052	0.0222	CbGeAlD
Vemurafenib—RAF1—telencephalon—germ cell cancer	0.000511	0.0218	CbGeAlD
Vemurafenib—Neoplasm malignant—Ifosfamide—germ cell cancer	0.000506	0.013	CcSEcCtD
Vemurafenib—RAF1—skin of body—germ cell cancer	0.000488	0.0208	CbGeAlD
Vemurafenib—RAF1—decidua—germ cell cancer	0.000485	0.0206	CbGeAlD
Vemurafenib—Hepatotoxicity—Cisplatin—germ cell cancer	0.000483	0.0124	CcSEcCtD
Vemurafenib—BRAF—testis—germ cell cancer	0.000462	0.0197	CbGeAlD
Vemurafenib—Vasculitis—Ifosfamide—germ cell cancer	0.000443	0.0113	CcSEcCtD
Vemurafenib—Hepatotoxicity—Etoposide—germ cell cancer	0.000442	0.0113	CcSEcCtD
Vemurafenib—RAF1—gonad—germ cell cancer	0.000427	0.0182	CbGeAlD
Vemurafenib—BRAF—cerebellum—germ cell cancer	0.000426	0.0182	CbGeAlD
Vemurafenib—RAF1—uterus—germ cell cancer	0.000424	0.0181	CbGeAlD
Vemurafenib—Rigors—Etoposide—germ cell cancer	0.000418	0.0107	CcSEcCtD
Vemurafenib—RAF1—pituitary gland—germ cell cancer	0.000416	0.0177	CbGeAlD
Vemurafenib—RAF1—medulla oblongata—germ cell cancer	0.000402	0.0171	CbGeAlD
Vemurafenib—Neoplasm—Ifosfamide—germ cell cancer	0.000391	0.01	CcSEcCtD
Vemurafenib—Arthritis—Bleomycin—germ cell cancer	0.000378	0.00968	CcSEcCtD
Vemurafenib—RAF1—adrenal gland—germ cell cancer	0.000372	0.0158	CbGeAlD
Vemurafenib—RAF1—midbrain—germ cell cancer	0.000367	0.0156	CbGeAlD
Vemurafenib—RAF1—bone marrow—germ cell cancer	0.00036	0.0153	CbGeAlD
Vemurafenib—RAF1—spinal cord—germ cell cancer	0.000358	0.0153	CbGeAlD
Vemurafenib—RAF1—female gonad—germ cell cancer	0.000347	0.0148	CbGeAlD
Vemurafenib—BRAF—brain—germ cell cancer	0.000346	0.0148	CbGeAlD
Vemurafenib—Polyp—Methotrexate—germ cell cancer	0.000336	0.00861	CcSEcCtD
Vemurafenib—BRAF—lymph node—germ cell cancer	0.000335	0.0143	CbGeAlD
Vemurafenib—Atrial fibrillation—Ifosfamide—germ cell cancer	0.000331	0.00848	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Vinblastine—germ cell cancer	0.000328	0.00841	CcSEcCtD
Vemurafenib—Folliculitis—Methotrexate—germ cell cancer	0.000325	0.00834	CcSEcCtD
Vemurafenib—RAF1—endocrine gland—germ cell cancer	0.000322	0.0137	CbGeAlD
Vemurafenib—RAF1—head—germ cell cancer	0.000318	0.0136	CbGeAlD
Vemurafenib—Pain in extremity—Ifosfamide—germ cell cancer	0.000314	0.00804	CcSEcCtD
Vemurafenib—Rash maculo-papular—Etoposide—germ cell cancer	0.00031	0.00795	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Dactinomycin—germ cell cancer	0.000308	0.0079	CcSEcCtD
Vemurafenib—RAF1—testis—germ cell cancer	0.000307	0.0131	CbGeAlD
Vemurafenib—Cyst—Methotrexate—germ cell cancer	0.000306	0.00784	CcSEcCtD
Vemurafenib—Paralysis—Methotrexate—germ cell cancer	0.000294	0.00754	CcSEcCtD
Vemurafenib—Weight decreased—Bleomycin—germ cell cancer	0.000287	0.00736	CcSEcCtD
Vemurafenib—RAF1—cerebellum—germ cell cancer	0.000284	0.0121	CbGeAlD
Vemurafenib—Toxic epidermal necrolysis—Ifosfamide—germ cell cancer	0.000283	0.00724	CcSEcCtD
Vemurafenib—ABCG2—trigeminal ganglion—germ cell cancer	0.000269	0.0115	CbGeAlD
Vemurafenib—Alopecia—Vinblastine—germ cell cancer	0.000266	0.00681	CcSEcCtD
Vemurafenib—Hepatotoxicity—Methotrexate—germ cell cancer	0.000265	0.00679	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Dactinomycin—germ cell cancer	0.000262	0.0067	CcSEcCtD
Vemurafenib—ABCC1—telencephalon—germ cell cancer	0.000255	0.0109	CbGeAlD
Vemurafenib—ORM1—bone marrow—germ cell cancer	0.000248	0.0106	CbGeAlD
Vemurafenib—ORM1—spinal cord—germ cell cancer	0.000247	0.0105	CbGeAlD
Vemurafenib—ABCC1—decidua—germ cell cancer	0.000242	0.0103	CbGeAlD
Vemurafenib—Infestation NOS—Ifosfamide—germ cell cancer	0.000242	0.0062	CcSEcCtD
Vemurafenib—Infestation—Ifosfamide—germ cell cancer	0.000242	0.0062	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Ifosfamide—germ cell cancer	0.00024	0.00614	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Ifosfamide—germ cell cancer	0.000237	0.00607	CcSEcCtD
Vemurafenib—RAF1—brain—germ cell cancer	0.000231	0.00983	CbGeAlD
Vemurafenib—Chills—Bleomycin—germ cell cancer	0.000228	0.00584	CcSEcCtD
Vemurafenib—ALB—adrenal gland—germ cell cancer	0.000225	0.00959	CbGeAlD
Vemurafenib—Alopecia—Bleomycin—germ cell cancer	0.000225	0.00575	CcSEcCtD
Vemurafenib—Erythema multiforme—Dactinomycin—germ cell cancer	0.000224	0.00574	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Etoposide—germ cell cancer	0.000223	0.00572	CcSEcCtD
Vemurafenib—RAF1—lymph node—germ cell cancer	0.000223	0.0095	CbGeAlD
Vemurafenib—ORM1—endocrine gland—germ cell cancer	0.000223	0.00949	CbGeAlD
Vemurafenib—Erythema—Bleomycin—germ cell cancer	0.000221	0.00567	CcSEcCtD
Vemurafenib—Connective tissue disorder—Ifosfamide—germ cell cancer	0.000213	0.00547	CcSEcCtD
Vemurafenib—Chills—Dactinomycin—germ cell cancer	0.000213	0.00545	CcSEcCtD
Vemurafenib—ABCC1—uterus—germ cell cancer	0.000212	0.00902	CbGeAlD
Vemurafenib—ABCG2—telencephalon—germ cell cancer	0.000211	0.00901	CbGeAlD
Vemurafenib—Vasculitis—Methotrexate—germ cell cancer	0.00021	0.00537	CcSEcCtD
Vemurafenib—Alopecia—Dactinomycin—germ cell cancer	0.000209	0.00536	CcSEcCtD
Vemurafenib—ABCC1—pituitary gland—germ cell cancer	0.000208	0.00886	CbGeAlD
Vemurafenib—Erythema—Dactinomycin—germ cell cancer	0.000206	0.00528	CcSEcCtD
Vemurafenib—Erythema multiforme—Ifosfamide—germ cell cancer	0.000205	0.00526	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Cisplatin—germ cell cancer	0.000204	0.00524	CcSEcCtD
Vemurafenib—Eye disorder—Ifosfamide—germ cell cancer	0.000203	0.0052	CcSEcCtD
Vemurafenib—Cardiac disorder—Ifosfamide—germ cell cancer	0.000202	0.00516	CcSEcCtD
Vemurafenib—ABCG2—decidua—germ cell cancer	0.0002	0.00854	CbGeAlD
Vemurafenib—Angiopathy—Ifosfamide—germ cell cancer	0.000197	0.00505	CcSEcCtD
Vemurafenib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.000196	0.00501	CcSEcCtD
Vemurafenib—Chills—Ifosfamide—germ cell cancer	0.000195	0.00499	CcSEcCtD
Vemurafenib—Cough—Bleomycin—germ cell cancer	0.000193	0.00494	CcSEcCtD
Vemurafenib—Alopecia—Ifosfamide—germ cell cancer	0.000192	0.00492	CcSEcCtD
Vemurafenib—Infestation—Etoposide—germ cell cancer	0.000191	0.00489	CcSEcCtD
Vemurafenib—Infestation NOS—Etoposide—germ cell cancer	0.000191	0.00489	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Etoposide—germ cell cancer	0.000189	0.00485	CcSEcCtD
Vemurafenib—Erythema—Ifosfamide—germ cell cancer	0.000189	0.00484	CcSEcCtD
Vemurafenib—Malnutrition—Ifosfamide—germ cell cancer	0.000189	0.00484	CcSEcCtD
Vemurafenib—Myalgia—Bleomycin—germ cell cancer	0.000188	0.00482	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Etoposide—germ cell cancer	0.000187	0.0048	CcSEcCtD
Vemurafenib—ALB—testis—germ cell cancer	0.000186	0.00793	CbGeAlD
Vemurafenib—ABCC1—adrenal gland—germ cell cancer	0.000186	0.00792	CbGeAlD
Vemurafenib—Decreased appetite—Vinblastine—germ cell cancer	0.000186	0.00476	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—germ cell cancer	0.000185	0.00474	CcSEcCtD
Vemurafenib—Connective tissue disorder—Cisplatin—germ cell cancer	0.000184	0.00471	CcSEcCtD
Vemurafenib—Constipation—Vinblastine—germ cell cancer	0.000183	0.00468	CcSEcCtD
Vemurafenib—Anaphylactic shock—Bleomycin—germ cell cancer	0.000181	0.00462	CcSEcCtD
Vemurafenib—Infection—Bleomycin—germ cell cancer	0.000179	0.00459	CcSEcCtD
Vemurafenib—Myalgia—Dactinomycin—germ cell cancer	0.000176	0.0045	CcSEcCtD
Vemurafenib—ABCG2—uterus—germ cell cancer	0.000175	0.00747	CbGeAlD
Vemurafenib—Eye disorder—Cisplatin—germ cell cancer	0.000175	0.00448	CcSEcCtD
Vemurafenib—Cardiac disorder—Cisplatin—germ cell cancer	0.000174	0.00445	CcSEcCtD
Vemurafenib—ABCC1—female gonad—germ cell cancer	0.000173	0.00738	CbGeAlD
Vemurafenib—ABCG2—pituitary gland—germ cell cancer	0.000172	0.00734	CbGeAlD
Vemurafenib—Photosensitivity—Methotrexate—germ cell cancer	0.000169	0.00433	CcSEcCtD
Vemurafenib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000169	0.00432	CcSEcCtD
Vemurafenib—Hypotension—Bleomycin—germ cell cancer	0.000169	0.00432	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—germ cell cancer	0.000167	0.00428	CcSEcCtD
Vemurafenib—ABCG2—medulla oblongata—germ cell cancer	0.000166	0.00708	CbGeAlD
Vemurafenib—Alopecia—Cisplatin—germ cell cancer	0.000165	0.00424	CcSEcCtD
Vemurafenib—Cough—Ifosfamide—germ cell cancer	0.000165	0.00423	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000164	0.00421	CcSEcCtD
Vemurafenib—CYP2D6—brainstem—germ cell cancer	0.000163	0.00696	CbGeAlD
Vemurafenib—Erythema—Cisplatin—germ cell cancer	0.000163	0.00417	CcSEcCtD
Vemurafenib—Malnutrition—Cisplatin—germ cell cancer	0.000163	0.00417	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—germ cell cancer	0.000162	0.00415	CcSEcCtD
Vemurafenib—Myalgia—Ifosfamide—germ cell cancer	0.000161	0.00412	CcSEcCtD
Vemurafenib—Arthralgia—Ifosfamide—germ cell cancer	0.000161	0.00412	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—germ cell cancer	0.00016	0.00411	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.00016	0.00409	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—germ cell cancer	0.000159	0.00408	CcSEcCtD
Vemurafenib—Hypersensitivity—Vinblastine—germ cell cancer	0.000157	0.00403	CcSEcCtD
Vemurafenib—Decreased appetite—Bleomycin—germ cell cancer	0.000157	0.00402	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—germ cell cancer	0.000156	0.00399	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—germ cell cancer	0.000155	0.00396	CcSEcCtD
Vemurafenib—Anaphylactic shock—Ifosfamide—germ cell cancer	0.000154	0.00395	CcSEcCtD
Vemurafenib—Chills—Etoposide—germ cell cancer	0.000154	0.00394	CcSEcCtD
Vemurafenib—ORM1—lymph node—germ cell cancer	0.000154	0.00656	CbGeAlD
Vemurafenib—ABCG2—adrenal gland—germ cell cancer	0.000154	0.00655	CbGeAlD
Vemurafenib—ABCC1—testis—germ cell cancer	0.000154	0.00655	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000153	0.00393	CcSEcCtD
Vemurafenib—Asthenia—Vinblastine—germ cell cancer	0.000153	0.00393	CcSEcCtD
Vemurafenib—Infection—Ifosfamide—germ cell cancer	0.000153	0.00393	CcSEcCtD
Vemurafenib—ABCG2—midbrain—germ cell cancer	0.000152	0.00647	CbGeAlD
Vemurafenib—Alopecia—Etoposide—germ cell cancer	0.000152	0.00388	CcSEcCtD
Vemurafenib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000151	0.00388	CcSEcCtD
Vemurafenib—Skin disorder—Ifosfamide—germ cell cancer	0.00015	0.00384	CcSEcCtD
Vemurafenib—ABCG2—bone marrow—germ cell cancer	0.000149	0.00634	CbGeAlD
Vemurafenib—ABCG2—spinal cord—germ cell cancer	0.000148	0.00631	CbGeAlD
Vemurafenib—Decreased appetite—Dactinomycin—germ cell cancer	0.000146	0.00375	CcSEcCtD
Vemurafenib—Diarrhoea—Vinblastine—germ cell cancer	0.000146	0.00375	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—germ cell cancer	0.000146	0.00375	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—germ cell cancer	0.000145	0.00372	CcSEcCtD
Vemurafenib—CYP2D6—telencephalon—germ cell cancer	0.000145	0.00618	CbGeAlD
Vemurafenib—Back pain—Etoposide—germ cell cancer	0.000144	0.0037	CcSEcCtD
Vemurafenib—Hypotension—Ifosfamide—germ cell cancer	0.000144	0.00369	CcSEcCtD
Vemurafenib—ABCG2—female gonad—germ cell cancer	0.000143	0.00611	CbGeAlD
Vemurafenib—Body temperature increased—Bleomycin—germ cell cancer	0.000143	0.00366	CcSEcCtD
Vemurafenib—ABCC1—cerebellum—germ cell cancer	0.000142	0.00605	CbGeAlD
Vemurafenib—Dizziness—Vinblastine—germ cell cancer	0.000141	0.00362	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000141	0.0036	CcSEcCtD
Vemurafenib—ALB—brain—germ cell cancer	0.00014	0.00595	CbGeAlD
Vemurafenib—Myalgia—Cisplatin—germ cell cancer	0.000139	0.00355	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000138	0.00353	CcSEcCtD
Vemurafenib—Vomiting—Vinblastine—germ cell cancer	0.000136	0.00348	CcSEcCtD
Vemurafenib—ALB—lymph node—germ cell cancer	0.000135	0.00575	CbGeAlD
Vemurafenib—Decreased appetite—Ifosfamide—germ cell cancer	0.000134	0.00344	CcSEcCtD
Vemurafenib—Headache—Vinblastine—germ cell cancer	0.000134	0.00343	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—germ cell cancer	0.000134	0.00343	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000133	0.00341	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—germ cell cancer	0.000133	0.00341	CcSEcCtD
Vemurafenib—Fatigue—Ifosfamide—germ cell cancer	0.000133	0.00341	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—germ cell cancer	0.000133	0.00341	CcSEcCtD
Vemurafenib—Hypersensitivity—Bleomycin—germ cell cancer	0.000133	0.00341	CcSEcCtD
Vemurafenib—Infection—Cisplatin—germ cell cancer	0.000132	0.00338	CcSEcCtD
Vemurafenib—Constipation—Ifosfamide—germ cell cancer	0.000132	0.00338	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—germ cell cancer	0.00013	0.00334	CcSEcCtD
Vemurafenib—Cough—Etoposide—germ cell cancer	0.00013	0.00334	CcSEcCtD
Vemurafenib—Asthenia—Bleomycin—germ cell cancer	0.00013	0.00332	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—germ cell cancer	0.000129	0.00331	CcSEcCtD
Vemurafenib—CYP1A2—endocrine gland—germ cell cancer	0.000128	0.00547	CbGeAlD
Vemurafenib—Pruritus—Bleomycin—germ cell cancer	0.000128	0.00327	CcSEcCtD
Vemurafenib—ABCG2—testis—germ cell cancer	0.000127	0.00542	CbGeAlD
Vemurafenib—Eosinophilia—Methotrexate—germ cell cancer	0.000127	0.00326	CcSEcCtD
Vemurafenib—Nausea—Vinblastine—germ cell cancer	0.000127	0.00325	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000126	0.00323	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—germ cell cancer	0.000124	0.00318	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—germ cell cancer	0.000124	0.00318	CcSEcCtD
Vemurafenib—Body temperature increased—Ifosfamide—germ cell cancer	0.000122	0.00312	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—germ cell cancer	0.000122	0.00312	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000121	0.0031	CcSEcCtD
Vemurafenib—Infection—Etoposide—germ cell cancer	0.000121	0.0031	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—germ cell cancer	0.000121	0.00309	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—germ cell cancer	0.000118	0.00303	CcSEcCtD
Vemurafenib—ABCG2—cerebellum—germ cell cancer	0.000117	0.00501	CbGeAlD
Vemurafenib—Photosensitivity reaction—Methotrexate—germ cell cancer	0.000117	0.003	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—germ cell cancer	0.000116	0.00296	CcSEcCtD
Vemurafenib—ABCC1—brain—germ cell cancer	0.000115	0.00491	CbGeAlD
Vemurafenib—Diarrhoea—Dactinomycin—germ cell cancer	0.000115	0.00295	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000115	0.00294	CcSEcCtD
Vemurafenib—Vomiting—Bleomycin—germ cell cancer	0.000115	0.00294	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—germ cell cancer	0.000114	0.00293	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—germ cell cancer	0.000114	0.00293	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—germ cell cancer	0.000114	0.00292	CcSEcCtD
Vemurafenib—Rash—Bleomycin—germ cell cancer	0.000114	0.00292	CcSEcCtD
Vemurafenib—Dermatitis—Bleomycin—germ cell cancer	0.000114	0.00291	CcSEcCtD
Vemurafenib—Hypersensitivity—Ifosfamide—germ cell cancer	0.000114	0.00291	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	0.000113	0.00291	CcSEcCtD
Vemurafenib—ABCC1—lymph node—germ cell cancer	0.000111	0.00475	CbGeAlD
Vemurafenib—Asthenia—Ifosfamide—germ cell cancer	0.000111	0.00284	CcSEcCtD
Vemurafenib—Pruritus—Ifosfamide—germ cell cancer	0.000109	0.0028	CcSEcCtD
Vemurafenib—Nausea—Bleomycin—germ cell cancer	0.000107	0.00275	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—germ cell cancer	0.000107	0.00274	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—germ cell cancer	0.000106	0.00272	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—germ cell cancer	0.000106	0.00271	CcSEcCtD
Vemurafenib—Diarrhoea—Ifosfamide—germ cell cancer	0.000106	0.0027	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000105	0.00269	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—germ cell cancer	0.000105	0.00269	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—germ cell cancer	0.000105	0.00269	CcSEcCtD
Vemurafenib—Constipation—Etoposide—germ cell cancer	0.000104	0.00267	CcSEcCtD
Vemurafenib—Dizziness—Ifosfamide—germ cell cancer	0.000102	0.00261	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—germ cell cancer	0.0001	0.00256	CcSEcCtD
Vemurafenib—CYP2D6—female gonad—germ cell cancer	9.83e-05	0.00419	CbGeAlD
Vemurafenib—Vomiting—Ifosfamide—germ cell cancer	9.81e-05	0.00251	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—germ cell cancer	9.8e-05	0.00251	CcSEcCtD
Vemurafenib—Rash—Ifosfamide—germ cell cancer	9.73e-05	0.00249	CcSEcCtD
Vemurafenib—Dermatitis—Ifosfamide—germ cell cancer	9.72e-05	0.00249	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—germ cell cancer	9.71e-05	0.00249	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—germ cell cancer	9.63e-05	0.00247	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—germ cell cancer	9.6e-05	0.00246	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—germ cell cancer	9.54e-05	0.00244	CcSEcCtD
Vemurafenib—ABCG2—brain—germ cell cancer	9.54e-05	0.00407	CbGeAlD
Vemurafenib—Cardiac disorder—Methotrexate—germ cell cancer	9.53e-05	0.00244	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—germ cell cancer	9.32e-05	0.00239	CcSEcCtD
Vemurafenib—CYP3A4—endocrine gland—germ cell cancer	9.29e-05	0.00396	CbGeAlD
Vemurafenib—Mediastinal disorder—Methotrexate—germ cell cancer	9.26e-05	0.00237	CcSEcCtD
Vemurafenib—ABCG2—lymph node—germ cell cancer	9.22e-05	0.00393	CbGeAlD
Vemurafenib—Chills—Methotrexate—germ cell cancer	9.22e-05	0.00236	CcSEcCtD
Vemurafenib—Nausea—Ifosfamide—germ cell cancer	9.16e-05	0.00235	CcSEcCtD
Vemurafenib—CYP2D6—endocrine gland—germ cell cancer	9.14e-05	0.0039	CbGeAlD
Vemurafenib—Diarrhoea—Cisplatin—germ cell cancer	9.1e-05	0.00233	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—germ cell cancer	9.08e-05	0.00233	CcSEcCtD
Vemurafenib—CYP2D6—head—germ cell cancer	9.03e-05	0.00385	CbGeAlD
Vemurafenib—Hypersensitivity—Etoposide—germ cell cancer	8.98e-05	0.0023	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—germ cell cancer	8.94e-05	0.00229	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—germ cell cancer	8.94e-05	0.00229	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—germ cell cancer	8.76e-05	0.00224	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—germ cell cancer	8.74e-05	0.00224	CcSEcCtD
Vemurafenib—CYP2D6—testis—germ cell cancer	8.72e-05	0.00372	CbGeAlD
Vemurafenib—Back pain—Methotrexate—germ cell cancer	8.65e-05	0.00222	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—germ cell cancer	8.62e-05	0.00221	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—germ cell cancer	8.46e-05	0.00217	CcSEcCtD
Vemurafenib—Rash—Cisplatin—germ cell cancer	8.39e-05	0.00215	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—germ cell cancer	8.38e-05	0.00215	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—germ cell cancer	8.34e-05	0.00214	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—germ cell cancer	8.06e-05	0.00206	CcSEcCtD
Vemurafenib—CYP2D6—cerebellum—germ cell cancer	8.05e-05	0.00343	CbGeAlD
Vemurafenib—Nausea—Cisplatin—germ cell cancer	7.9e-05	0.00202	CcSEcCtD
Vemurafenib—Cough—Methotrexate—germ cell cancer	7.8e-05	0.002	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—germ cell cancer	7.75e-05	0.00198	CcSEcCtD
Vemurafenib—Rash—Etoposide—germ cell cancer	7.68e-05	0.00197	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—germ cell cancer	7.67e-05	0.00197	CcSEcCtD
Vemurafenib—Headache—Etoposide—germ cell cancer	7.63e-05	0.00196	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—germ cell cancer	7.61e-05	0.00195	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—germ cell cancer	7.61e-05	0.00195	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	7.56e-05	0.00194	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—germ cell cancer	7.3e-05	0.00187	CcSEcCtD
Vemurafenib—Infection—Methotrexate—germ cell cancer	7.25e-05	0.00186	CcSEcCtD
Vemurafenib—Nausea—Etoposide—germ cell cancer	7.24e-05	0.00185	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—germ cell cancer	7.16e-05	0.00183	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—germ cell cancer	7.09e-05	0.00182	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—germ cell cancer	6.82e-05	0.00175	CcSEcCtD
Vemurafenib—RAF1—Interleukin-11 Signaling Pathway—HRAS—germ cell cancer	6.76e-05	0.00212	CbGpPWpGaD
Vemurafenib—RAF1—Signalling to ERKs—HRAS—germ cell cancer	6.76e-05	0.00212	CbGpPWpGaD
Vemurafenib—BRAF—CDC42 signaling events—HRAS—germ cell cancer	6.74e-05	0.00211	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—FGFR3—germ cell cancer	6.71e-05	0.0021	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—CD9—germ cell cancer	6.68e-05	0.00209	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KITLG—germ cell cancer	6.66e-05	0.00209	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	6.65e-05	0.0017	CcSEcCtD
Vemurafenib—BRAF—B Cell Receptor Signaling Pathway—MYC—germ cell cancer	6.61e-05	0.00207	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	6.57e-05	0.00206	CbGpPWpGaD
Vemurafenib—CYP2D6—brain—germ cell cancer	6.54e-05	0.00279	CbGeAlD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	6.52e-05	0.00204	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—germ cell cancer	6.42e-05	0.00201	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—germ cell cancer	6.42e-05	0.00201	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-2 signaling—HRAS—germ cell cancer	6.41e-05	0.00201	CbGpPWpGaD
Vemurafenib—Decreased appetite—Methotrexate—germ cell cancer	6.34e-05	0.00163	CcSEcCtD
Vemurafenib—RAF1—Signaling by ERBB4—FGFR3—germ cell cancer	6.32e-05	0.00198	CbGpPWpGaD
Vemurafenib—ALB—SLC-mediated transmembrane transport—SLC2A3—germ cell cancer	6.31e-05	0.00198	CbGpPWpGaD
Vemurafenib—Gastrointestinal disorder—Methotrexate—germ cell cancer	6.3e-05	0.00161	CcSEcCtD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—germ cell cancer	6.29e-05	0.00197	CbGpPWpGaD
Vemurafenib—Fatigue—Methotrexate—germ cell cancer	6.29e-05	0.00161	CcSEcCtD
Vemurafenib—RAF1—Signaling by NGF—FGF4—germ cell cancer	6.24e-05	0.00196	CbGpPWpGaD
Vemurafenib—RAF1—TSH signaling pathway—MYC—germ cell cancer	6.22e-05	0.00195	CbGpPWpGaD
Vemurafenib—ALB—SLC-mediated transmembrane transport—SLC22A3—germ cell cancer	6.22e-05	0.00195	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	6.21e-05	0.00195	CbGpPWpGaD
Vemurafenib—RAF1—IL-3 Signaling Pathway—HRAS—germ cell cancer	6.2e-05	0.00194	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—KIT—germ cell cancer	6.16e-05	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—FGFR3—germ cell cancer	6.03e-05	0.00189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—germ cell cancer	6e-05	0.00188	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—FGFR3—germ cell cancer	6e-05	0.00188	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—FGFR3—germ cell cancer	5.97e-05	0.00187	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	5.96e-05	0.00187	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—FGFR3—germ cell cancer	5.94e-05	0.00186	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	5.94e-05	0.00186	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	5.91e-05	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—KIT—germ cell cancer	5.89e-05	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	5.87e-05	0.00184	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	5.82e-05	0.00182	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—KIT—germ cell cancer	5.8e-05	0.00182	CbGpPWpGaD
Vemurafenib—Body temperature increased—Methotrexate—germ cell cancer	5.77e-05	0.00148	CcSEcCtD
Vemurafenib—RAF1—IL2-mediated signaling events—HRAS—germ cell cancer	5.74e-05	0.0018	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—FGFR3—germ cell cancer	5.59e-05	0.00175	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—FGFR3—germ cell cancer	5.59e-05	0.00175	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	5.59e-05	0.00175	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—FGFR3—germ cell cancer	5.54e-05	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—KIT—germ cell cancer	5.54e-05	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—KIT—germ cell cancer	5.51e-05	0.00173	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—FGFR3—germ cell cancer	5.51e-05	0.00173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	5.49e-05	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—SOX2—germ cell cancer	5.49e-05	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—KIT—germ cell cancer	5.48e-05	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—FGFR3—germ cell cancer	5.47e-05	0.00171	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—KIT—germ cell cancer	5.46e-05	0.00171	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—HRAS—germ cell cancer	5.42e-05	0.0017	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PVRL2—germ cell cancer	5.41e-05	0.0017	CbGpPWpGaD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—MYC—germ cell cancer	5.39e-05	0.00169	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Methotrexate—germ cell cancer	5.38e-05	0.00138	CcSEcCtD
Vemurafenib—RAF1—Kit receptor signaling pathway—HRAS—germ cell cancer	5.34e-05	0.00167	CbGpPWpGaD
Vemurafenib—Asthenia—Methotrexate—germ cell cancer	5.24e-05	0.00134	CcSEcCtD
Vemurafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—HRAS—germ cell cancer	5.2e-05	0.00163	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	5.2e-05	0.00163	CbGpPWpGaD
Vemurafenib—BRAF—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	5.19e-05	0.00163	CbGpPWpGaD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—TP53—germ cell cancer	5.17e-05	0.00162	CbGpPWpGaD
Vemurafenib—Pruritus—Methotrexate—germ cell cancer	5.16e-05	0.00132	CcSEcCtD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	5.13e-05	0.00161	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—KIT—germ cell cancer	5.13e-05	0.00161	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KIT—germ cell cancer	5.13e-05	0.00161	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KITLG—germ cell cancer	5.13e-05	0.00161	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	5.12e-05	0.0016	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—TP53—germ cell cancer	5.09e-05	0.0016	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KIT—germ cell cancer	5.09e-05	0.00159	CbGpPWpGaD
Vemurafenib—RAF1—Endothelins—HRAS—germ cell cancer	5.07e-05	0.00159	CbGpPWpGaD
Vemurafenib—BRAF—Integrin-mediated Cell Adhesion—HRAS—germ cell cancer	5.06e-05	0.00159	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KIT—germ cell cancer	5.06e-05	0.00158	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KIT—germ cell cancer	5.04e-05	0.00158	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KIT—germ cell cancer	5.02e-05	0.00157	CbGpPWpGaD
Vemurafenib—Diarrhoea—Methotrexate—germ cell cancer	4.99e-05	0.00128	CcSEcCtD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	4.99e-05	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—MYC—germ cell cancer	4.99e-05	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	4.95e-05	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—HRAS—germ cell cancer	4.95e-05	0.00155	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SCNN1A—germ cell cancer	4.9e-05	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—HRAS—germ cell cancer	4.89e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—mTOR signaling pathway—HRAS—germ cell cancer	4.89e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—TSH signaling pathway—HRAS—germ cell cancer	4.89e-05	0.00153	CbGpPWpGaD
Vemurafenib—BRAF—ErbB1 downstream signaling—HRAS—germ cell cancer	4.87e-05	0.00153	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	4.87e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—BCR signaling pathway—HRAS—germ cell cancer	4.83e-05	0.00151	CbGpPWpGaD
Vemurafenib—Dizziness—Methotrexate—germ cell cancer	4.83e-05	0.00124	CcSEcCtD
Vemurafenib—BRAF—Disease—SLC2A3—germ cell cancer	4.82e-05	0.00151	CbGpPWpGaD
Vemurafenib—RAF1—NCAM signaling for neurite out-growth—HRAS—germ cell cancer	4.77e-05	0.0015	CbGpPWpGaD
Vemurafenib—RAF1—CDC42 signaling events—HRAS—germ cell cancer	4.66e-05	0.00146	CbGpPWpGaD
Vemurafenib—Vomiting—Methotrexate—germ cell cancer	4.64e-05	0.00119	CcSEcCtD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—MYC—germ cell cancer	4.64e-05	0.00145	CbGpPWpGaD
Vemurafenib—Rash—Methotrexate—germ cell cancer	4.6e-05	0.00118	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—germ cell cancer	4.6e-05	0.00118	CcSEcCtD
Vemurafenib—Headache—Methotrexate—germ cell cancer	4.57e-05	0.00117	CcSEcCtD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—MYC—germ cell cancer	4.57e-05	0.00143	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	4.55e-05	0.00143	CbGpPWpGaD
Vemurafenib—RAF1—Leptin signaling pathway—HRAS—germ cell cancer	4.41e-05	0.00138	CbGpPWpGaD
Vemurafenib—Nausea—Methotrexate—germ cell cancer	4.33e-05	0.00111	CcSEcCtD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	4.29e-05	0.00135	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—MYC—germ cell cancer	4.26e-05	0.00133	CbGpPWpGaD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—HRAS—germ cell cancer	4.24e-05	0.00133	CbGpPWpGaD
Vemurafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—germ cell cancer	4.19e-05	0.00131	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	4.11e-05	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—germ cell cancer	4.1e-05	0.00128	CbGpPWpGaD
Vemurafenib—RAF1—IRS-mediated signalling—HRAS—germ cell cancer	3.99e-05	0.00125	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events—HRAS—germ cell cancer	3.88e-05	0.00122	CbGpPWpGaD
Vemurafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—germ cell cancer	3.87e-05	0.00121	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	3.85e-05	0.00121	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—HRAS—germ cell cancer	3.81e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—FGFR3—germ cell cancer	3.81e-05	0.00119	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—TP53—germ cell cancer	3.81e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—HRAS—germ cell cancer	3.75e-05	0.00117	CbGpPWpGaD
Vemurafenib—RAF1—IGF1R signaling cascade—HRAS—germ cell cancer	3.75e-05	0.00117	CbGpPWpGaD
Vemurafenib—RAF1—Insulin receptor signalling cascade—HRAS—germ cell cancer	3.75e-05	0.00117	CbGpPWpGaD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—MYC—germ cell cancer	3.73e-05	0.00117	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CD9—germ cell cancer	3.6e-05	0.00113	CbGpPWpGaD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	3.59e-05	0.00113	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—MYC—germ cell cancer	3.57e-05	0.00112	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—FGF4—germ cell cancer	3.56e-05	0.00112	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—germ cell cancer	3.52e-05	0.0011	CbGpPWpGaD
Vemurafenib—RAF1—Integrin-mediated Cell Adhesion—HRAS—germ cell cancer	3.5e-05	0.0011	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KIT—germ cell cancer	3.5e-05	0.0011	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—germ cell cancer	3.5e-05	0.0011	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	3.44e-05	0.00108	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—HRAS—germ cell cancer	3.44e-05	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—FGF4—germ cell cancer	3.42e-05	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	3.37e-05	0.00106	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—HRAS—germ cell cancer	3.37e-05	0.00106	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SLC2A3—germ cell cancer	3.33e-05	0.00104	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—HRAS—germ cell cancer	3.32e-05	0.00104	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SLC2A3—germ cell cancer	3.3e-05	0.00104	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—HRAS—germ cell cancer	3.29e-05	0.00103	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PVRL2—germ cell cancer	3.28e-05	0.00103	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—HRAS—germ cell cancer	3.21e-05	0.00101	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	3.21e-05	0.00101	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	3.16e-05	0.00099	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—HRAS—germ cell cancer	3.13e-05	0.000982	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	3.13e-05	0.00098	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—HRAS—germ cell cancer	3.11e-05	0.000975	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—HRAS—germ cell cancer	3.03e-05	0.00095	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—MYC—germ cell cancer	2.95e-05	0.000923	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—germ cell cancer	2.93e-05	0.00092	CbGpPWpGaD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—HRAS—germ cell cancer	2.93e-05	0.000919	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KITLG—germ cell cancer	2.92e-05	0.000916	CbGpPWpGaD
Vemurafenib—ALB—SLC-mediated transmembrane transport—AVP—germ cell cancer	2.91e-05	0.000912	CbGpPWpGaD
Vemurafenib—BRAF—Transmission across Chemical Synapses—HRAS—germ cell cancer	2.91e-05	0.000912	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	2.84e-05	0.00089	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KITLG—germ cell cancer	2.81e-05	0.00088	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGF4—germ cell cancer	2.77e-05	0.000867	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SLC2A3—germ cell cancer	2.77e-05	0.000867	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—germ cell cancer	2.75e-05	0.000862	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—AVP—germ cell cancer	2.75e-05	0.000861	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SLC22A3—germ cell cancer	2.72e-05	0.000854	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—AVP—germ cell cancer	2.72e-05	0.000854	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	2.71e-05	0.000849	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—germ cell cancer	2.68e-05	0.000839	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—HRAS—germ cell cancer	2.66e-05	0.000834	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	2.66e-05	0.000833	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—OXT—germ cell cancer	2.66e-05	0.000833	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—HRAS—germ cell cancer	2.62e-05	0.00082	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—HRAS—germ cell cancer	2.55e-05	0.000798	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—HRAS—germ cell cancer	2.51e-05	0.000786	CbGpPWpGaD
Vemurafenib—BRAF—Disease—H2AFZ—germ cell cancer	2.47e-05	0.000774	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	2.45e-05	0.000769	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SLC2A3—germ cell cancer	2.43e-05	0.000763	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—germ cell cancer	2.42e-05	0.000758	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—HRAS—germ cell cancer	2.41e-05	0.000754	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SLC22A3—germ cell cancer	2.4e-05	0.000751	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—AVP—germ cell cancer	2.4e-05	0.000751	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—HRAS—germ cell cancer	2.39e-05	0.00075	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—HRAS—germ cell cancer	2.38e-05	0.000747	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	2.38e-05	0.000747	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—HRAS—germ cell cancer	2.37e-05	0.000743	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HRAS—germ cell cancer	2.36e-05	0.000739	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KITLG—germ cell cancer	2.27e-05	0.000712	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—OXT—germ cell cancer	2.27e-05	0.000711	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—HRAS—germ cell cancer	2.23e-05	0.000698	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CRABP1—germ cell cancer	2.22e-05	0.000696	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HRAS—germ cell cancer	2.22e-05	0.000695	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—HRAS—germ cell cancer	2.22e-05	0.000695	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	2.22e-05	0.000695	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—HRAS—germ cell cancer	2.2e-05	0.000689	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—HRAS—germ cell cancer	2.18e-05	0.000685	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	2.18e-05	0.000684	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—HRAS—germ cell cancer	2.18e-05	0.000683	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—FGFR3—germ cell cancer	2.17e-05	0.000681	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—HRAS—germ cell cancer	2.17e-05	0.00068	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—germ cell cancer	2.1e-05	0.000657	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—FGFR3—germ cell cancer	2.09e-05	0.000654	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGF4—germ cell cancer	2.07e-05	0.00065	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—germ cell cancer	2.01e-05	0.000631	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KIT—germ cell cancer	1.99e-05	0.000625	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	1.97e-05	0.000616	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CRABP1—germ cell cancer	1.95e-05	0.000613	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGF4—germ cell cancer	1.94e-05	0.000607	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KIT—germ cell cancer	1.92e-05	0.0006	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGF4—germ cell cancer	1.91e-05	0.0006	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	1.9e-05	0.000595	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGF4—germ cell cancer	1.9e-05	0.000595	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	1.89e-05	0.000594	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AVP—germ cell cancer	1.82e-05	0.000571	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—H2AFZ—germ cell cancer	1.73e-05	0.000542	CbGpPWpGaD
Vemurafenib—RAF1—Disease—H2AFZ—germ cell cancer	1.71e-05	0.000536	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KITLG—germ cell cancer	1.7e-05	0.000534	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—H2AFZ—germ cell cancer	1.69e-05	0.000531	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGFR3—germ cell cancer	1.69e-05	0.000529	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KITLG—germ cell cancer	1.59e-05	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KITLG—germ cell cancer	1.57e-05	0.000493	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—OXT—germ cell cancer	1.57e-05	0.000492	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KITLG—germ cell cancer	1.56e-05	0.000488	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AVP—germ cell cancer	1.56e-05	0.000487	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KIT—germ cell cancer	1.55e-05	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—germ cell cancer	1.54e-05	0.000483	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—germ cell cancer	1.54e-05	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—germ cell cancer	1.51e-05	0.000474	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC2A3—germ cell cancer	1.5e-05	0.000471	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC22A3—germ cell cancer	1.48e-05	0.000464	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—AVP—germ cell cancer	1.48e-05	0.000464	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—germ cell cancer	1.37e-05	0.000429	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF4—germ cell cancer	1.34e-05	0.00042	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR3—germ cell cancer	1.27e-05	0.000397	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	1.24e-05	0.000389	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	1.22e-05	0.000383	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CRABP1—germ cell cancer	1.21e-05	0.000378	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—H2AFZ—germ cell cancer	1.2e-05	0.000375	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR3—germ cell cancer	1.18e-05	0.000371	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR3—germ cell cancer	1.17e-05	0.000366	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KIT—germ cell cancer	1.16e-05	0.000364	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR3—germ cell cancer	1.16e-05	0.000363	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KITLG—germ cell cancer	1.1e-05	0.000345	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KIT—germ cell cancer	1.09e-05	0.00034	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AVP—germ cell cancer	1.08e-05	0.000337	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KIT—germ cell cancer	1.07e-05	0.000336	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KIT—germ cell cancer	1.06e-05	0.000333	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A3—germ cell cancer	1.05e-05	0.000329	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC22A3—germ cell cancer	1.03e-05	0.000324	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—germ cell cancer	1e-05	0.000314	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CRABP1—germ cell cancer	9.96e-06	0.000312	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—germ cell cancer	9.76e-06	0.000306	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—germ cell cancer	9.58e-06	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—germ cell cancer	8.62e-06	0.00027	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—germ cell cancer	8.53e-06	0.000267	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CRABP1—germ cell cancer	8.43e-06	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—germ cell cancer	8.28e-06	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR3—germ cell cancer	8.18e-06	0.000256	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	8.11e-06	0.000254	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	7.99e-06	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—germ cell cancer	7.51e-06	0.000235	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—germ cell cancer	6.7e-06	0.00021	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CRABP1—germ cell cancer	6.51e-06	0.000204	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—germ cell cancer	5.97e-06	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—germ cell cancer	5.9e-06	0.000185	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—germ cell cancer	5.85e-06	0.000183	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—germ cell cancer	5.5e-06	0.000172	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—germ cell cancer	5.39e-06	0.000169	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—germ cell cancer	5.15e-06	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—germ cell cancer	5.02e-06	0.000157	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—germ cell cancer	4.91e-06	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—germ cell cancer	4.69e-06	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—germ cell cancer	4.64e-06	0.000145	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—germ cell cancer	4.6e-06	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—germ cell cancer	4.13e-06	0.00013	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—germ cell cancer	3.39e-06	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—germ cell cancer	3.25e-06	0.000102	CbGpPWpGaD
